Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7874 USD | +5.46% | +0.37% | -61.40% |
May. 09 | Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $1.74M, vs. Street Est of $2.85M | MT |
May. 09 | Transcript : Gritstone bio, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 6.45 times its current sales, is high.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-61.40% | 85.49M | D+ | ||
-2.32% | 90.45B | A- | ||
+3.68% | 41.45B | A- | ||
-10.90% | 33.57B | B- | ||
+58.05% | 25.73B | A | ||
-19.56% | 14.73B | C | ||
-9.06% | 12.82B | B- | ||
-11.34% | 11.7B | D+ | ||
-43.53% | 11.44B | B | ||
+3.75% | 8.79B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GRTS Stock
- Ratings Gritstone bio, Inc.